Needham & Company
-
Needham & Company Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Sees RP-A501 as "Major Value Driver"
-
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
-
Needham & Company Starts Rocket Pharmaceuticals (RCKT) at Buy
-
Pre-Open Stock Movers 04/16: (ELF) (CRSP) (GH) Higher; (BRS) (WVE) (IP) Lower (more...)

